EGFR and glioblastoma: The INTELLANCE-2/EORTC 1410 study [108] was a randomized phase II study analyzing this drug alone or in association with temozolomide versus the standard treatment of Lomustine or temozolomide in recurrent EGFR-amplified GBM patients.